UNH
UnitedHealth Group Incorporated
UNH has a slight edge over URGN overall, supported by lower modeled downside and stronger modeled upside.
URGN
UroGen Pharma Ltd.
URGN offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
URGN Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
URGN's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
URGN PE Valuation
URGN has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 15x next year's earnings.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
URGN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
URGN has the edge over UNH on the outlook, with more favorable revenue expectations.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over URGN on earnings quality, reporting a profit while its opponent remains loss making.
URGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.79 | — |
| Q3 2026 | -$1.33 | +$2.13 |
| Q2 2026 | -$1.99 | +$1.33 |
| Q1 2026 | -$2.76 | +$0.42 |
| Q4 2025 | -$3.21 | +$0.02 |
| Q3 2025 | -$3.46 | -$0.13 |
| Q2 2025 | -$3.32 | +$0.14 |
| Q1 2025 | -$3.18 | +$0.40 |
| Q4 2024 | -$3.23 | +$0.68 |
URGN is still losing money, but far less than before: $1.33 per share over the past year, against $6.40 at its worst in late 2020.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
URGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $89M | +224% |
| Q2 2026 | $72.5M | +199% |
| Q1 2026 | $51M | +152% |
| Q4 2025 | $37.8M | +54% |
| Q3 2025 | $27.5M | +9% |
| Q2 2025 | $24.2M | +11% |
| Q1 2025 | $20.3M | +7.8% |
| Q4 2024 | $24.6M | +4.4% |
URGN has the edge over UNH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.4% | +109 points |
| Q2 2026 | 0.1% | +171 points |
| Q1 2026 | -40% | +143 points |
| Q4 2025 | -51% | +62 points |
| Q3 2025 | -100% | -30 points |
| Q2 2025 | -171% | -53 points |
| Q1 2025 | -182% | -45 points |
| Q4 2024 | -113% | -51 points |
URGN has the edge over UNH on profitability, with a higher operating margin.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over URGN on cash generation, producing positive trailing cash flow while its opponent burns cash.
URGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$15.3M | +$27.1M |
| Q2 2026 | -$33.1M | +$6.9M |
| Q1 2026 | -$45.4M | -$3.3M |
| Q4 2025 | -$38.3M | -$24.6M |
| Q3 2025 | -$42.4M | -$14.6M |
| Q2 2025 | -$40M | -$16.1M |
| Q1 2025 | -$42.1M | -$10.3M |
| Q4 2024 | -$13.7M | -$682K |
URGN has burned cash in almost every quarter: −$132M over the past year, against −$138M the year before.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over URGN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
URGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +178K shares |
| 1 year | +5.2% | +2.5M shares |
| 3 years | +115% | +27.1M shares |
| 5 years | +126% | +28.2M shares |
| Available history | +146% | +30M shares |
URGN has 51M diluted shares, up 5.2% from a year ago.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
URGN Net Leverage
URGN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
URGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.3 | Neutral |
| Stochastic | 3.5 | Oversold |
URGN's weekly RSI is 36 (neutral) and its Stochastic is 4 (oversold).
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
URGN PE vs Healthcare Sector
URGN has no meaningful PE right now: it lost money over the past year.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over URGN on trend strength, trading above more of its moving averages.
URGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $34.1 | 23% below |
| 20 week MA | $39.2 | 33% below |
| 50 week MA | $29.7 | 11% below |
| 100 week MA | $21.9 | 20% above |
| 200 week MA | $17.7 | 49% above |
URGN has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 49% above its 200-week average.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over URGN on returns for 2026, with the stronger performance.
URGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $33.1 | $18.9 | -43% |
| 2021 | $18.9 | $9.49 | -50% |
| 2022 | $9.49 | $8.14 | -14% |
| 2023 | $8.14 | $15.0 | +84% |
| 2024 | $15.0 | $10.8 | -28% |
| 2025 | $10.8 | $23.0 | +114% |
| 2026 YTD | $23.0 | $26.4 | +15% |
URGN's yearly returns have swung widely, from +114% in 2025 to −50% in 2021. It's up 15% so far in 2026.